Form 4: Nurix Therapeutics Director, Lori Anne Kunkel, Reports Disposition of Common Stock
SEC Form 4 Filing
Director Lori Anne Kunkel reported the disposition of 54,027 shares of Nurix Therapeutics common stock on July 17, 2024.
Summary
- On July 18, 2024, a Form 4 filing was submitted to the SEC regarding changes in beneficial ownership of Nurix Therapeutics, Inc. [NRIX] securities.
- The filing pertains to Lori Anne Kunkel, a director of Nurix Therapeutics.
- On July 17, 2024, Ms. Kunkel disposed of 54,027 shares of common stock.
- The transaction was a disposition (D) at a price of $0 per share.
Sentiment
Score: 5
Explanation: This is a neutral report of a stock transaction by a company director. The sentiment is neither positive nor negative without additional context.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders.
Stakeholder Impact
- The disposition of shares by a director could be perceived differently by stakeholders, depending on the reason for the sale and the overall context of the company's performance.
Key Dates
| Date | Description |
|---|---|
| 07/17/2024 | Date of transaction: Disposition of common stock. |
| 07/18/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.